Blog
RSS FeedPosted by Michael Wonder on 26 Mar 2017
Mood Disorders Society of Canada urges action on improving Canadians' access to life-saving medications
24 March 2017 - Mood Disorders Society of Canada today released a groundbreaking brief recommending action to improve Canadians' access ...
Posted by Michael Wonder on 24 Mar 2017
Hope of B.C. coverage for life-saving cystic fibrosis drug dashed
23 March 2017 - 'It's about dollars,' says father of 16-year-old who claims son's life was changed by access to the ...
Posted by Michael Wonder on 23 Mar 2017
CADTH recommends reimbursement of Stelara for new indication
21 March 2017 - The cost of treatment with ustekinumab should not exceed the drug plan cost of the least costly ...
Posted by Michael Wonder on 23 Mar 2017
British Columbia lists Epclusa on public drug plan to treat all six genotypes of chronic hepatitis C infection
21 March 2017 - British Columbia also broadens access for patients with less advanced disease who have other health conditions. ...
Posted by Michael Wonder on 21 Mar 2017
Launch of new Canadian Guidelines for the Economic Evaluation of Health Technologies
21 March 2017 - This release marks the first update to the Guidelines since the third edition was published in ...
Posted by Michael Wonder on 16 Mar 2017
Call for feedback: new drugs for type 2 diabetes: second-line therapy : a therapeutic review update
15 March 2017 - A report on new drugs for second-line therapy for 2 diabetes: a therapeutic review update is now ...
Posted by Michael Wonder on 28 Feb 2017
Universal public coverage of essential drugs would improve health care, research suggests
27 February 2017 - Price of medication for high blood pressure, diabetes sometimes blocks patients' treatment. ...
Posted by Michael Wonder on 22 Feb 2017
Deal reduces price of life-saving hepatitis C drugs for Canadians
21 February 2017 - Tens of thousands of Canadian patients with mild versions of chronic hepatitis C could soon receive ...
Posted by Michael Wonder on 30 Jan 2017
CADTH recommends UCB's Brivlera
25 January 2017 - CADTH's first outcome for 2017 is in favour of the reimbursement of brivaracetam. ...
Posted by Michael Wonder on 22 Jan 2017
Call for feedback on a therapeutic review update of new second-line therapies for type 2 diabetes mellitus
20 January 2017 - Two draft science reports on new drugs for type 2 diabetes: second-line therapy : a therapeutic review ...
Posted by Michael Wonder on 16 Jan 2017
Health minister vows to save Canadians 'billions' on drug prices
13 January 2017 - Analysis shows Canadians pay substantially more for pharmaceuticals made by Canadian company. ...
Posted by Michael Wonder on 16 Jan 2017
Rare public hearing highlights concerns over explosion of high-priced specialty drugs in Canada
16 January 2017 - Matt George remembers vividly how it felt to receive his first infusion of Soliris, a drug ...
Posted by Michael Wonder on 23 Nov 2016
CADTH recommends listing of Quinsair
23 November 2016 - CADTH recommends use of levofloxacin inhalation solution. ...
Posted by Michael Wonder on 02 Nov 2016
Jardiance recommended by CADTH for use by patients with type 2 diabetes mellitus at high risk of cardiovascular disease
26 October 2016 - CADTH publishes final recommendation on prevention of cardiovascular mortality in type 2 diabetes mellitus. ...
Posted by Michael Wonder on 01 Nov 2016
CADTH supports the use of Entyvio in Crohn's disease
31 October 2016 - Takeda's Entyvio clocks up another CADTH recommendation. ...